# US 2010/0168419 A1 · Diacylglycerol Acyltransferase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168419 A1
- Document ID: US20100168419A1
- Status: Published application
- Kind: A1
- Application number: 12/722,065
- Filed: 2010-03-11
- Published: 2010-07-01
- Earliest claimed: 2005-11-28
- Inventors: David Robert Bolin; Adrian Wai-Hing Cheung; Fariborz Firooznia; Matthew Michael Hamilton; Shiming Li; Lee Apostle McDermott; Yimin Qian; Weiya Yun
- Web page: https://patentgrep.com/patent/US20100168419A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

## Claims

### Claim 1

A compound of the formula (I):
wherein:
R1 is unsubstituted aryl, aryl substituted with a group selected from the group consisting of alkyl, —O-alkyl, haloalkoxy, methoxy-ethoxy and halogen, heteroaryl, alkyl or cycloalkyl;
R2 is C or N;
R3 is C, N, S or O;
R4 is C, O, S or N;
R5 is C, N or S;
R6 is H, alkyl, halogen, haloalkyl, thioalkyl or hydrogen;
R7 is
at least one of R8 or R9 is N; and the other is carbon;
R10 is —NR11R12, O-alkyl, hydroxy-dimethylethylamino, hydroxyl-methylethylamino, cyclohept-2-ylamino, morpholino, thiomorpholino, oxothiomorpholino, dioxothiomorpholino, alkyl-carbamoyl-alkyl-amino, difluoroazetidine, ethoxyazetidine, azetidin-3-yloxy acetic acid tert-butyl ether, azetidine-3-yloxy acetic acid hydrochloride, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of amino, amide, —N(CH3)C(O)CH3, cyclopropanecarbonyl-methyl, —OCH3, —OCH2C(O)OC(CH3)3, OCH2C(O)OH, —CH2OH, —CH2OCH3 and —OH;
R11 is H, lower alkyl, alkyl ether, alkyl-aryl, trifluoromethyl, methoxymethyl, cyclopropylmethoxy-ethyl, ethoxymethyl, —CH2CH2CN, alkyl alcohol, acyl, cycloalkyl, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of —OCH3, —CH2OH, —CH2OCH3, —OCH2C(O)OC(CH3)3, —OCH2C(O)OH and —OH;
R12 is H or lower alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
R1 is unsubstituted aryl or aryl substituted with a group selected from the group consisting of alkyl and halogen;
R2 is C;
R3 is N;
R4 is O;
R5 is C;
R6 is alkyl;
R7 is
at least one of R8 or R9 is N; and the other is carbon;
R10 is —NR11R12, O-alkyl, hydroxy-dimethylethylamino, hydroxyl-methylethylamino, cyclohept-2-ylamino, morpholino, thiomorpholino, oxothiomorpholino, dioxothiomorpholino, alkyl-carbamoyl-alkyl-amino, difluoroazetidine, ethoxyazetidine, azetidin-3-yloxy acetic acid tert-butyl ether, azetidine-3-yloxy acetic acid hydrochloride, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of amino, amide, —N(CH3)C(O)CH3, cyclopropanecarbonyl-methyl, —OCH3, —OCH2C(O)OC(CH3)3, OCH2C(O)OH, —CH2OH, —CH2OCH3 and —OH;
R11 is H, lower alkyl, alkyl ether, alkyl-aryl, trifluoromethyl, methoxymethyl, cyclopropylmethoxy-ethyl, ethoxymethyl, —CH2CH2CN, alkyl alcohol, acyl, cycloalkyl, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of —OCH3, —CH2OH, —CH2OCH3, —OCH2C(O)OC(CH3)3, —OCH2C(O)OH and —OH;
R12 is H or lower alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein:
R1 is unsubstituted aryl or aryl substituted with a group selected from the group consisting of alkyl and halogen;
R2 is C;
R3 is O;
R4 is N;
R5 is C;
R6 is H, alkyl, halogen, haloalkyl, thioalkyl or hydrogen;
R7 is
at least one of R8 or R9 is N; and the other is carbon;
R10 is —NR11R12, O-alkyl, hydroxy-dimethylethylamino, hydroxyl-methylethylamino, cyclohept-2-ylamino, morpholino, thiomorpholino, oxothiomorpholino, dioxothiomorpholino, alkyl-carbamoyl-alkyl-amino, difluoroazetidine, ethoxyazetidine, azetidin-3-yloxy acetic acid tert-butyl ether, azetidine-3-yloxy acetic acid hydrochloride, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of amino, amide, —N(CH3)C(O)CH3, cyclopropanecarbonyl-methyl, —OCH3, —OCH2C(O)OC(CH3)3, OCH2C(O)OH, —CH2OH, —CH2OCH3 and —OH;
R11 is H, lower alkyl, alkyl ether, alkyl-aryl, trifluoromethyl, methoxymethyl, cyclopropylmethoxy-ethyl, ethoxymethyl, —CH2CH2CN, alkyl alcohol, acyl, cycloalkyl, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of —OCH3, —CH2OH, —CH2OCH3, —OCH2C(O)OC(CH3)3, —OCH2C(O)OH and —OH;
R12 is H or lower alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein:
R1 is unsubstituted aryl, aryl substituted with a group selected from the group consisting of alkyl, —O-alkyl, haloalkoxy, methoxy-ethoxy and halogen, heteroaryl, alkyl or cycloalkyl;
R2 is C or N;
R3 is C, N, S or O;
R4 is C, O, S or N;
R5 is C, N or S;
R6 is H, alkyl, halogen, haloalkyl, thioalkyl or absent hydrogen;
R7 is
at least one of R8 or R9 is N; and the other is carbon;
R10 is —NR11R12;
R11 is H, lower alkyl, alkyl ether, alkyl alcohol, acyl or a 5- or 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of −OCH3, —CH2OH, —CH2OCH3 and —OH;
R12 is H or lower alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein:
R1 is unsubstituted aryl, aryl substituted with a group selected from the group consisting of alkyl, —O-alkyl, haloalkoxy, methoxy-ethoxy and halogen, heteroaryl, alkyl or cycloalkyl;
R2 is C or N;
R3 is C, N, S or O;
R4 is C, O, S or N;
R5 is C, N or S;
R6 is H, alkyl, halogen, haloalkyl, thioalkyl or hydrogen;
R7 is
at least one of R8 or R9 is N; and the other is carbon;
R10 is —NR11R12, O-alkyl, hydroxy-dimethylethylamino, hydroxyl-methylethylamino, cyclohept-2-ylamino, morpholino, thiomorpholino, oxothiomorpholino, dioxothiomorpholino, alkyl-carbamoyl-alkyl-amino, difluoroazetidine, ethoxyazetidine, azetidin-3-yloxy acetic acid tert-butyl ether, azetidine-3-yloxy acetic acid hydrochloride, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of amino, amide, —N(CH3)C(O)CH3, cyclopropanecarbonyl-methyl, —OCH3, —OCH2C(O)OC(CH3)3, OCH2C(O)OH, —CH2OH, —CH2OCH3 and —OH;
R11 is H, lower alkyl, alkyl ether, alkyl-aryl, trifluoromethyl, methoxymethyl, cyclopropylmethoxy-ethyl, ethoxymethyl, —CH2CH2CN, alkyl alcohol, acyl, cycloalkyl, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of —OCH3, —CH2OH, —CH2OCH3, —OCH2C(O)OC(CH3)3, —OCH2C(O)OH and —OH;
R12 is H or lower alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein:
R1 is unsubstituted aryl, aryl substituted with a group selected from the group consisting of alkyl, —O-alkyl, haloalkoxy, methoxy-ethoxy and halogen, heteroaryl, alkyl or cycloalkyl;
R2 is C or N;
R3 is C, N, S or O;
R4 is C, O, S or N;
R5 is C, N or S;
R6 is H, alkyl, halogen, haloalkyl, thioalkyl or hydrogen;
R7 is
at least one of R8 or R9 is N; and the other is carbon;
R10 is —NR11R12, O-alkyl, hydroxy-dimethylethylamino, hydroxyl-methylethylamino, cyclohept-2-ylamino, morpholino, thiomorpholino, oxothiomorpholino, dioxothiomorpholino, alkyl-carbamoyl-alkyl-amino, difluoroazetidine, ethoxyazetidine, azetidin-3-yloxy acetic acid tert-butyl ether, azetidine-3-yloxy acetic acid hydrochloride, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of amino, amide, —N(CH3)C(O)CH3, cyclopropanecarbonyl-methyl, —OCH3, —OCH2C(O)OC(CH3)3, OCH2C(O)OH, —CH2OH, —CH2OCH3 and —OH;
R11 is H, lower alkyl, alkyl ether, alkyl-aryl, trifluoromethyl, methoxymethyl, cyclopropylmethoxy-ethyl, ethoxymethyl, —CH2CH2CN, alkyl alcohol, acyl, cycloalkyl, or a 4- to 6-membered cyclic ring having from 1 to 3 hetero ring atoms selected from the group consisting of S, N and O, unsubstituted or substituted with a group selected from the group consisting of —OCH3, —CH2OH, —CH2OCH3, CH2C(O)OC(CH3)3, —OCH2C(O)OH and —OH;
R12 is H or lower alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R6 is —CF3.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R10 is —(CH3)(CH2)nOCH3, —N(CH3)CH2C(O)OCH3, —N(CH3)CH2C(O)NHCH3, —N(CH3)C(O)CH3, —N(CH3)(CH2)nCH3, —NH(CH2)nCH3, —N(CH2CH3)(CH2)nOCH3, diethylamino, —N(CH3)C(O)CH2OCH3, —N(CH3)CH(CH3)CH2OCH3, —N(CH3)(CH2)nO, —N(CH2)nO, —NCH2(CH3)CH2O or —N-tetrahydropyran; wherein n is 1, 2 or 3.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein said compound is 5-phenyl-2-trifluoromethyl-furan-3-carboxylic acid (6-morpholin-4-yl-pyridin-3-yl)-amide,

### Claim at position 10

10-13. (canceled)

### Claim 14 (depends on 1)

The compound according to claim 1, wherein said compound is 2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid {2-[(2-methoxy-ethyl)-methyl-amino]-pyrimidin-5-yl}-amide.

### Claim at position 12

15-20. (canceled)

### Claim 21 (depends on 1)

The compound of claim 1 wherein said compound has the formula
wherein R1, R6 and R10 are as above.

### Claim 22 (depends on 1)

The compound of claim 1 wherein said compound has the formula
wherein R1, R6 and R10 are as above.

### Claim 23 (depends on 1)

The compound of claim 1 wherein said compound has the formula:
wherein R1, R6 and R10 are as above.
